The secondary objective was to determine whether the magnitude of the pharmacokinetic interaction was influenced by P-glycoprotein genetic polymorphism.
其次，分析药物药代动力学的改变程度是否与P -糖蛋白的遗传多态性有关。
The secondary objective was to determine whether the magnitude of the pharmacokinetic interaction was influenced by P-glycoprotein genetic polymorphism.
其次，分析药物药代动力学的改变程度是否与P -糖蛋白的遗传多态性有关。
应用推荐